A phase 1, open-label, drug –drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

ConclusionRucaparib 600  mg BID weakly increased the plasma exposure to rosuvastatin or oral contraceptives. Rucaparib safety profile when coadministered with rosuvastatin or oral contraceptives was consistent with that of rucaparib monotherapy. Dose adjustments of rosuvastatin and oral contraceptives are not necessary wh en coadministered with rucaparib.ClinicalTrials.gov NCT03954366;Date of registration May 17, 2019.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research